Literature DB >> 3107607

Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease.

G Pizzolo, M Chilosi, F Vinante, F Dazzi, M Lestani, G Perona, F Benedetti, G Todeschini, C Vincenzi, L Trentin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3107607      PMCID： PMC2001695          DOI： 10.1038/bjc.1987.83

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  12 in total

1.  Natural killer cell activity during the course of disease in patients with Hodgkin's disease.

Authors:  I Frydecka
Journal:  Cancer       Date:  1985-12-15       Impact factor: 6.860

2.  Inhibition of transformation of normal lymphocytes by plasma factor from patients with Hodgkin's disease and cancer.

Authors:  P G Scheurlen; W Schneider; A Pappas
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

3.  Interleukin 2 regulates its own receptors.

Authors:  K A Smith; D A Cantrell
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

4.  Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease.

Authors:  H Kamesaki; S Fukuhara; E Tatsumi; H Uchino; H Yamabe; H Miwa; S Shirakawa; M Hatanaka; T Honjo
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

5.  Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease.

Authors:  S M Hsu; K Yang; E S Jaffe
Journal:  Am J Pathol       Date:  1985-02       Impact factor: 4.307

6.  Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia.

Authors:  S J Korsmeyer; W C Greene; J Cossman; S M Hsu; J P Jensen; L M Neckers; S L Marshall; A Bakhshi; J M Depper; W J Leonard; E S Jaffe; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

7.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

Authors:  H Stein; D Y Mason; J Gerdes; N O'Connor; J Wainscoat; G Pallesen; K Gatter; B Falini; G Delsol; H Lemke
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

8.  Lack of natural killer cell activity in hairy cell leukemia patients and partial restoration with interleukin-2.

Authors:  W C Hooper; R F Barth; N T Shah
Journal:  Cancer       Date:  1986-03-01       Impact factor: 6.860

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease.

Authors:  G Pizzolo; M Chilosi; G Semenzato; F Caligaris-Cappio; L Fiore-Donati; G Perona; G Janossy
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640
View more
  12 in total

1.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

2.  Evolution of the levels of soluble interleukin-2 receptors during Plasmodium falciparum and P. vivax malaria.

Authors:  P Deloron; J P Lepers; P Coulanges
Journal:  J Clin Microbiol       Date:  1989-08       Impact factor: 5.948

3.  Hematopoietic growth factor receptors.

Authors:  J H Shieh; M A Moore
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

4.  Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer.

Authors:  P Marino; M Cugno; A Preatoni; P Cori; A Rosti; L Frontini; M Cicardi
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

5.  Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.

Authors:  S Viviani; E Camerini; V Bonfante; A Santoro; M Balzarotti; M Fornier; L Devizzi; P Verderio; P Valagussa; G Bonadonna
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

6.  Interleukin 2 receptor in patients with localized and systemic parasitic diseases.

Authors:  O Josimovic-Alasevic; H Feldmeier; K Zwingenberger; G Harms; H Hahn; M Shrisuphanunt; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

7.  Membrane-bound and soluble IL-2 receptors (p55 and p75 chains) on peripheral blood mononuclear cells from patients with solid malignancies.

Authors:  G Mantovani; A Macciò; G Astara; L Contini; S Esu; S Littera; V Arangino; P Lai; E Proto; G Pusceddu
Journal:  Cell Biophys       Date:  1993 Jan-Jun

8.  Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1 alpha, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies.

Authors:  G Mantovani; A Macciò; P Lai; M Ghiani; E Turnu; G S Del Giacco
Journal:  Cell Biophys       Date:  1995-08

9.  Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes.

Authors:  Sebastian Seidler; Henning W Zimmermann; Ralf Weiskirchen; Christian Trautwein; Frank Tacke
Journal:  BMC Gastroenterol       Date:  2012-04-24       Impact factor: 3.067

10.  Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.

Authors:  P Lissoni; S Barni; R Rescaldani; F Rovelli; G Tancini
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.